565453-39-6

Basic information

• Product Name: Vildagliptin iMpurity K
• Synonyms: Vildagliptin Impurity A;Vildagliptin Amide Impurity;(S)-1-[2-(-3-hydroxy-adaMantan-1-ylaMino)-acetyl]-pyrrolidine-2-carboxylic acid;Vildagliptin iMpurity K;(2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carboxamide;1-(2-((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carboxamide
• CAS NO: 565453-39-6
• Molecular Formula: C17H26N2O4
• Molecular Weight: 322.39934
• Mol File: 565453-39-6.mol

Chemical Properties

• Melting Point: 94-96 °C
• Boiling Point: 585.9±50.0 °C(Predicted)
• Appearance: /
• Density: 1.31±0.1 g/cm3(Predicted)
• PKA: 15.05±0.40(Predicted)
• CAS DataBase Reference: Vildagliptin iMpurity K(CAS DataBase Reference)
• NIST Chemistry Reference: Vildagliptin iMpurity K(565453-39-6)
• EPA Substance Registry System: Vildagliptin iMpurity K(565453-39-6)

Safety Data

• Hazardous Substances Data: 565453-39-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Vildagliptin iMpurity K is used as a reference compound for quality control and analytical testing in the pharmaceutical industry. It helps ensure the purity and safety of Vildagliptin, the active ingredient in anti-hyperglycemic medications, by providing a benchmark for impurity levels.
Additionally, understanding the properties and effects of Vildagliptin iMpurity K can contribute to the development of improved drug formulations and the identification of potential side effects or interactions with other compounds in the treatment of diabetes.

Upstream product

• 702-82-9 3-aminoadamantan-1-ol 
• 214398-99-9 (S)-1-(2-chloroacetyl) pyrrolidine-2-carboxamide 
• 7531-52-4 L-prolinamide 
• 1032564-18-3 [(3‐hydroxytricyclo[3.3.1.13,7]decan‐1‐yl)amino]acetic acid 
• 147-85-3 L-proline 
• 38074-72-5 (S)-1-(2-chloroacetyl)pyrrolidine-2-carboxylic acid methyl ester 
• 768-94-5 1-Adamantanamine 
• 1044676-63-2 vildagliptin 

Relevant articles and documents

A preparation method of the peculiar smell degradation impurity

The invention discloses a method for preparing vildagliptin degradation impurities. The method comprises the following steps: dissolving vildagliptin I in a solvent, adding an alkali solution, heating to 30-100 DEG C and reacting for 1-10 hours to obtain vildagliptin amide II. The method is short in synthetic route, simple and high in operability; the product meeting quality standards can be easily obtained through simple purification.

NOVEL ECONOMIC PROCESS FOR VILDAGLIPTIN

The present invention relates to a commercially viable novel process for manufacturing Vildagliptin in high yield with high chemical and chiral purity.

NEW PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VILDAGLIPTIN

A new process for the synthesis of vildagliptin a via a novel intermediate formed by salification of prolinamide with haloacetic acid.

1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

Dipeptidyl peptidase IV (DPP-IV) inhibition has the potential to become a valuable therapy for type 2 diabetes. The synthesis and structure - activity relationship of a new DPP-IV inhibitor class, N-substituted-glycyl-2-cyanopyrrolidines, are described as well as the path that led from clinical development compound 1-[2-[5-cyanopyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)pyrrolidine (NVP-DPP728, 8c) to its follow-up, 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)pyrrolidine (NVP-LAF237, 12j). The pharmacological profile of 12j in obese Zucker fa/fa rats along with pharmacokinetic profile comparison of 8c and 12j in normal cynomolgus monkeys is discussed. The results suggest that 12j is a potent, stable, selective DPP-IV inhibitor possessing excellent oral bioavailability and potent antihyperglycemic activity with potential for once-a-day administration.